In a report released on March 11, Craig Abbott from Kepler Capital maintained a Buy rating on Stroeer SE & Co. KGaA (0MYZ – Research ...

Kepler Capital analyst Christian Faitz maintained a Buy rating on Henkel AG & Co. KGaA (0IZC – Research Report) on March 11 and set a ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Henkel AG & Co KGaA (HELKF) reports robust financial performance with a 25% EPS increase and announces a significant share ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

This page uses Cookies. For proper functioning of the page Cookies are needed. You agree to using Cookies by clicking "OK".

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

The Federal Circuit reinstated a challenge of a Merck KGaA unit’s pigment patent by South Korea-based CQV Co. on Monday, ...